US Executive Officer Management Changes SEC — October 14, 2026

14-10-2026

Verastem Oncology announced that Michael P. Bailey will succeed Daniel Paterson as President and CEO effective January 1, 2027, as part of a planned succession plan. Paterson, who served as CEO since 2023 and with the company since 2011 (15-year tenure per the release), will retire, remain on the Board, and serve as an advisor. The company highlighted commercial progress for AVMAPKI FAKZYNJA CO-PACK and clinical advancement of VS-7375, though the release contains no financial results or quantitative performance figures.

• · Bailey has served on Verastem's Board since May 2026 and previously led AVEO as CEO from January 2015, including the FOTIVDA approval and launch in 2021
• · VS-7375 is in registration-directed Phase 2 trials (TARGET-D 201 in pancreatic, 202 in NSCLC, 203 in colorectal) and a Phase 3 trial in first-line metastatic pancreatic cancer is expected to begin later in 2026
• · VS-7375 holds FDA Fast Track Designation for KRAS G12D-mutated PDAC (first-line and previously treated) and previously treated NSCLC
• · AVMAPKI FAKZYNJA CO-PACK received accelerated FDA approval on May 8, 2025 for KRAS-mutated recurrent LGSOC; continued approval may depend on a confirmatory trial
• · Paterson will remain on the Board and as an advisor after stepping down as CEO

14-10-2026

Lisata Therapeutics appointed Jeffrey Farrow, a veteran biopharma CFO and Chief Strategy Officer of Tarsus Pharmaceuticals, to its Board of Directors effective October 13, 2026, filling a newly created seat that expands the Board from seven to eight members. Mr. Farrow will also serve on the Audit Committee and has been determined independent under Nasdaq rules. The filing contains no financial results, so no period-over-period performance figures are reported.

• · Mr. Farrow was appointed as a Class III director on the recommendation of the Nominating and Corporate Governance Committee
• · Mr. Farrow chairs the audit committee at Achieve Life Sciences and is also a director of Clover Biopharmaceuticals (HKEX)
• · Mr. Farrow was CFO of Global Blood Therapeutics from 2016 to 2022 through its acquisition by Pfizer
• · Mr. Farrow previously served as CFO of ZS Pharma (through AstraZeneca acquisition in 2015) and CFO of Hyperion Therapeutics (2010 to 2015)
• · Mr. Farrow holds a B.A. in business administration from California State University, Fullerton and is an inactive CPA

14-10-2026

Compass, Inc. appointed technology executive Sissie Hsiao, a nearly 20-year Google veteran who led development of the Gemini app, to its Board of Directors. Director Charles Phillips resigned effective October 9, 2026 to devote more time to outside commitments, with no disagreement with the Company; Frank Martell succeeds him as Lead Independent Director and Steven Sordello as Chair of the Nominating and Corporate Governance Committee.

• · Sissie Hsiao previously served as Vice President and General Manager of Google's Display, Video, and App Advertising businesses
• · Charles Phillips had served as a Director since August 2020 and Lead Independent Director since February 2021, and also sat on the Audit Committee
• · Frank Martell has served on the Board since November 2021 and chairs the Audit Committee; he is also President, CEO and a director of SmartRent, Inc.
• · Steven Sordello has served on the Board since November 2020 and continues on the Audit Committee

14-10-2026

XTI Aerospace (Nasdaq: XTIA) appointed Dr. Allan Evans, CEO and director of Unusual Machines (NYSE American: UMAC), as a director and Chairman of its Board, returning the Board to five members. Jonathan Ornstein was designated Vice Chairman, and Jeremy Schneiderman remains Interim CEO. The filing contains no financial results or quantitative performance data.

• · Dr. Evans has been CEO and a director of Unusual Machines since December 2023
• · Dr. Evans was COO of Red Cat Holdings from 2021 to 2023 and CEO of Fat Shark from 2017 until its 2020 acquisition by Red Cat
• · Dr. Evans holds a PhD in Electrical Engineering from the University of Michigan
• · Management cites the transition away from foreign drone manufacturers as a key opportunity, and the filing flags reliance on DJI and other foreign suppliers as a risk

14-10-2026

State Street reported Q3 2026 diluted EPS of $3.69, up 33% YoY, on total revenue of $4.0 billion (up 13% YoY, down 1% QoQ) with a 34.6% pre-tax margin and no notable items. Growth was broad-based, led by Management fees (+20%) and FX trading services (+17%), but Other fee revenue fell 29% YoY and QoQ, Foreign exchange trading services fell 14% QoQ, Provision for credit losses was a $4 million release, and CET1 declined 0.3 percentage points YoY to 11.0% due to capital return and higher RWA. The filing also lists an officer change item (Item 5.02), which the provided text does not detail.

• · Other fee revenue fell 29% YoY and QoQ, primarily due to market-related adjustments, a declining line not highlighted in the summary.
• · FX trading services revenue declined 14% QoQ, reflecting a lower mix of emerging markets revenue.
• · Information systems and communications expenses rose 15% YoY, driven by technology and infrastructure investments and volume-related costs.
• · Occupancy expenses fell 4% YoY on real estate footprint optimization but rose 6% QoQ on one-time items.
• · Net interest margin declined 1 basis point QoQ to 1.12%, though it rose 16 basis points YoY.
• · ROE and ROTCE both declined QoQ (down 0.3 and 0.4 percentage points respectively) despite strong YoY gains.
• · Announced agreement to acquire Santander CACEIS Latam Securities Services joint venture, subject to regulatory approvals and closing conditions.
• · Item 5.02 (officer change) is listed in the filing metadata, but the provided excerpt does not describe the officer or the change.

14-10-2026

ExchangeRight Income Fund disclosed that its manager, ExchangeRight Real Estate, LLC, appointed Timothy Williams as Chief Administrative Officer of both the manager and the Company, effective October 7, 2026. Williams, 36, joined ExchangeRight in 2021 as Senior Controller and most recently served as Director of Asset Management. No employment agreement was entered into, and the filing discloses no family relationships or related-party transactions requiring Item 404(a) disclosure.

• · Williams previously led asset management, overseeing tenant relations, strategic leasing initiatives, and physical property stewardship
• · Prior experience includes six years at McCoy Group leading the transportation division accounting function and contributing to acquisitions and divestitures
• · Holds B.A. and Master's degrees in Accounting from the University of Northern Iowa (2013) and received the Elijah Watt Sells Award for the May 2013 CPA exam

14-10-2026

Yext, Inc. disclosed that on October 11, 2026, its Board approved a performance-based nonstatutory stock option for CEO Michael Walrath covering 11,000,000 shares at a $7.00 exercise price, a premium to the $6.93 closing price on October 9, 2026. The option vests only if the stock hits 14 escalating price targets from $21.00 to $88.08 over five to ten years, and requires stockholder approval within twelve months or it is forfeited. The grant is designed as Walrath's sole new equity compensation for ten years, though no performance results or current-period financials are reported in this filing.

• · Option is granted outside the 2016 Equity Incentive Plan and requires stockholder approval within twelve months; if not obtained, the option is forfeited in full
• · Each tranche requires the average closing price to meet the target over 180 consecutive days and also over 30 consecutive days within a defined window
• · Tranches 1 must be achieved within five years, tranches 2-6 within seven years, and tranches 7-14 within ten years
• · Earned shares face retention requirements released over three anniversaries (tranches 1-8) or every six months (tranches 9-14)
• · Change-in-control, death/disability, and no-cause/good-reason termination each trigger distinct vesting treatments, including a 250,000 or 1,000,000 bonus share kicker tied to a 15% or 25% compounded annual growth rate

14-10-2026

All In FutureTech Alliance, Inc. (NASDAQ: AIFA, formerly Allied Gaming & Entertainment Inc.) held its 2026 Annual Meeting of Stockholders on October 12, 2026. Stockholders elected six directors, ratified ZH CPA, LLC as auditor for FY2026, approved a 1,284,063-share increase in the 2019 Equity Incentive Plan (from 627,218 to 1,911,281 shares), and approved the issuance of 707,730 shares to President Yangyang Li under a May 2, 2026 Share Issuance and Reimbursement Agreement. Item 5.02 flags compensatory arrangements, and the Li share issuance was approved only after excluding his related votes under the Contractual Standard.

• · Proposal 4 required three separate approval standards (Nasdaq, Bylaws, and Contractual); the Contractual Standard excluded Li-related votes and the Li share issuance passed under all three, with 1,570,120 FOR votes and 25,174 AGAINST.
• · Director votes showed zero AGAINST votes for all six nominees, with abstentions ranging from 12,652 to 82,071 and identical broker non-votes of 647,508 across all directors.
• · The Proxy Statement was filed with the SEC on September 14, 2026, and mailed to stockholders on or about September 15, 2026.
• · Item 5.02 is triggered by the compensatory plan amendment and Li share issuance rather than an officer departure or new appointment; no officer departure is reported in the filing.
• · The filing is signed by Roy Anderson as CFO, and the company's name on the cover page is All In FutureTech Alliance, Inc., indicating a corporate name change from Allied Gaming & Entertainment Inc.

14-10-2026

Sprouts Farmers Market announced that James Bahrenburg stepped down as Chief Technology Officer effective October 12, 2026, with the Company stating the departure was not due to any disagreement on operations, policies, or practices. Bahrenburg will serve as an advisor through March 31, 2027 to support an orderly transition, retaining equity vesting and cash bonus eligibility during that period, and remains eligible for severance under the Company's Amended and Restated Executive Severance and Change in Control Plan.

• · Departure is effective October 12, 2026; the filing is dated October 14, 2026
• · Advisory period runs through March 31, 2027
• · Existing equity awards continue to vest during the advisory period
• · Company states the departure was not the result of any disagreement with the Company

14-10-2026

Longeveron Inc. (Nasdaq: LGVN) disclosed that Chief Medical Officer Dr. Nataliya Agafonova informed management on October 7, 2026 of her decision to step down, with the departure effective October 14, 2026. The filing is a routine Item 5.02 disclosure of a C-suite departure and does not report any financial results, compensation terms, or successor appointment.

• · Departure date of the Chief Medical Officer is effective October 14, 2026, one week after notice was given on October 7, 2026
• · The filing does not name a successor or interim CMO, and no compensatory arrangements or separation terms are disclosed
• · Filing is made under Item 5.02(b) only; no director election or appointment is reported

14-10-2026

Jackson Financial Inc. (NYSE: JXN) announced that its Board of Directors elected Donald C. ("Don") Templin as a new independent director, appointing him to the Audit and Compensation committees. Templin is a former EVP and CFO of Voya Financial and of Marathon Petroleum, and a former PwC audit partner with 26 years as a CPA.

• · Templin holds a Bachelor of Arts in Accounting from Grove City College
• · Templin is a former Executive Vice President and CFO of Voya Financial and Executive Vice President and CFO of Marathon Petroleum Corporation
• · Templin was Managing Partner of PwC's Audit Practice in Georgia, Alabama and Tennessee

14-10-2026

Green Dot Corporation (GDOT) disclosed that General Counsel Amy Pugh notified the company on October 8, 2026 of her decision to resign to pursue another professional opportunity, effective November 2, 2026. The filing is a routine Item 5.02 officer departure disclosure and does not include financial results or performance metrics.

• · Resignation notice dated October 8, 2026; effective date November 2, 2026
• · Filing does not state a successor or interim General Counsel
• · Stated reason is pursuit of another professional opportunity; no disagreement with the company is disclosed

14-10-2026

Enliven Therapeutics appointed Kristine Ball to its Board of Directors, effective immediately, ahead of its planned initiation of the pivotal Phase 3 ENABLE-2 trial of relcobatinib before year-end 2026. Ms. Ball brings over 20 years of biopharma executive experience in corporate strategy, finance and commercial readiness, and she chairs the Audit Committee at Oruka Therapeutics. The announcement contains no financial results or quantified performance metrics.

• · Ms. Ball chairs the Audit Committee at Oruka Therapeutics and previously served on the boards of Atreca and Forty Seven
• · Ms. Ball earned a Bachelor of Science from Babson College
• · Relcobatinib is being developed for previously treated chronic myeloid leukemia (CML)
• · Enliven recently announced FDA alignment on the final design of ENABLE-2

14-10-2026

Mattel amended the October 2026 offer letter with newly appointed CEO Roger Lynch, moving his start date and equity grants to October 12, 2026 following recent external developments. The amendment also raises his change-in-control severance multiplier from 2x to 2.99x for terminations on or before December 31, 2028 and adds a Section 280G excise tax gross-up. The filing contains no performance metrics, so there is no mixed or declining financial data to report.

• · Start Date moved to October 12, 2026, and equity grants now vest-date to that day rather than the last trading day of the start month
• · Section 280G excise tax gross-up protection added for a change of control on or before December 31, 2028
• · Amendment filed as Exhibit 10.1 to the 8-K; original offer letter and CEO appointment were disclosed in the September 30, 2026 8-K

14-10-2026

Comtech Telecommunications announced leadership changes ahead of the anticipated closing of the sale of most of its Satellite & Space Communications segment to Gilat Satellite Networks. Richard Nyren (joined October 8, 2026) will succeed Michael Bondi as CFO after the Q1 fiscal 2027 Form 10-Q, currently anticipated by December 10, 2026, and Amy Rothstein-Hovey (joined October 1, 2026) will succeed Don Walther as Chief Legal Officer and Corporate Secretary upon completion of the S&S transaction. Both departing executives are leaving amicably, and no financial performance metrics are disclosed in this filing.

• · Nyren's CFO transition is tied to the filing of the Q1 fiscal 2027 Form 10-Q, currently anticipated by December 10, 2026
• · Rothstein-Hovey becomes Chief Legal Officer and Corporate Secretary immediately after the anticipated S&S transaction completion
• · Bondi and Walther are remaining through transition periods to assist with handover of responsibilities
• · The S&S sale to Gilat was agreed in June 2026 and remains subject to regulatory approvals and customary closing conditions
• · Nyren will be based in Allerium's Broomfield, Colorado office; Rothstein-Hovey in Allerium's Seattle office
• · Rothstein-Hovey currently serves as an independent director of Arlo Technologies

14-10-2026

KB Home's Management Development and Compensation Committee approved long-term incentive grants on October 8, 2026, consisting solely of performance-based restricted stock units (PSUs) to three named executive officers: Robert V. McGibney (135,227 target shares), Jeffrey T. Mezger (112,689 target shares), and Brian J. Woram (21,411 target shares). The PSUs vest over a three-year performance period (December 1, 2026 to November 30, 2029) based on cumulative adjusted EPS (40%), average adjusted ROIC (35%), and relative revenue growth versus high-production homebuilder peers (25%), with payouts ranging from 0% to 200% of target. The filing does not report any change in officer status itself, so the classification as Officer Change is preliminary and reflects compensation rather than an appointment or departure.

• · PSU recipients receive a cash dividend equivalent for each vested share, based on dividends with record dates between grant and performance determination
• · Full vesting occurs upon death, disability, or attaining at least 55 years of age with 15 consecutive years of service
• · Recipients forfeit all rights upon other termination of service

14-10-2026

Andersen Group Inc. (ANDG) disclosed under Item 5.02 that it appointed two longtime senior executives, Daniel DePaoli and Peter Coscia, to its Board of Directors effective October 13, 2026, expanding the Board from 8 to 10 directors. The company characterized the additions as strengthening operational expertise to support its global growth strategy, though the filing contains no quantitative financial performance data.

• · DePaoli has held senior leadership at Andersen since 2002, previously serving as a tax partner at Arthur Andersen, with 30+ years of professional services experience.
• · Coscia oversees operations across the eastern United States and Caribbean, previously served as Managing Director of the Metro New York office, and has 35+ years of experience including roles at Arthur Andersen and Deloitte.
• · The filing states the appointments add operational expertise alongside the existing outside directors' capital markets, governance, and business experience.
• · The company identified organic growth, acquisitions, and global professional services expansion as strategic priorities aligned with the new appointments.

14-10-2026

Akebia Therapeutics announced that Nicholas Grund, Senior Vice President and Chief Commercial Officer, has resigned for personal reasons, effective November 6, 2026. In connection with his departure, Mr. Grund entered into a Consulting Agreement effective on the Resignation Date, under which he will provide consulting and advisory services until April 30, 2027, compensated at an hourly rate.

• · Resignation notice given October 7, 2026; resignation effective November 6, 2026
• · Consulting Agreement signed October 13, 2026, with a consulting period ending April 30, 2027
• · Either party may terminate the consulting arrangement early: the Company with at least 10 days' written notice, or Mr. Grund with at least 30 days' written notice
• · Mr. Grund's consulting compensation is hourly; no dollar amount is disclosed in the filing

14-10-2026

Alector, Inc. (ALEC) disclosed that its Board approved an option repricing on October 13, 2026, covering roughly 4.05 million stock options held by continuing employees with exercise prices above $1.87. Eligible options were repriced to $1.87 per share, the closing price on the Effective Date, subject to a one-year Retention Period during which exercise requires payment of the original, higher exercise price. The repricing addresses a situation in which a majority of employee options were underwater.

• · Original exercise prices for the CEO's repriced options ranged from $6.48 to $23.70 per share; the CAO's ranged from $9.46 to $23.70 per share.
• · Previously outstanding exercise prices for repriced options ranged from $6.48 to $33.11 per share.
• · Retention Period ends at the earliest of one year after the Effective Date, a Change in Control, or the holder's death or Disability.
• · Expiration dates, vesting criteria, and share counts of the Eligible Options were unchanged by the repricing.

14-10-2026

PC Connection (CNXN) announced that Matt Zafirovski joined as President and Chief Operating Officer effective October 12, 2026, reporting to CEO Timothy McGrath, who remains CEO after previously holding the President and CEO roles. Zafirovski previously served as CEO of Tusker, where he helped nearly double revenue through organic growth and acquisitions. The filing contains no financial results, so no period-over-period performance comparisons are reported.

• · Zafirovski's appointment is effective October 12, 2026, two days before the October 14, 2026 announcement
• · McGrath previously served as President and CEO and will continue solely as CEO following the appointment
• · At Tusker, Zafirovski first served as COO and was later promoted to CEO
• · Zafirovski holds an MBA from Northwestern's Kellogg School of Management and a bachelor's degree in public policy from Duke University

14-10-2026

Kulicke & Soffa's Management Development and Compensation Committee approved an amended and restated Incentive Compensation Plan effective for fiscal 2027. The Plan replaces Net Income and Operating Margin (each 50%) with Operating Profit and Gross Margin (each 50%) as corporate performance measures, and adds a 15% individual goal component for Executive Leadership Team awards (85% corporate financial performance). The filing discloses no monetary amounts, officer departures, or new appointments.

• · Business unit scorecards may be tailored by growth phase and strategic priorities, subject to the company's scorecard governance process
• · Individual goals for ELT members are intended to reflect measurable business or financial outcomes aligned with strategic objectives
• · The Plan is filed as Exhibit 10.1 and is a management contract or compensatory plan

14-10-2026

Bubblr, Inc. (BBLR) disclosed that director Steve Morris resigned from its board, effective the close of business on October 2, 2026. The filing is signed by Robert L. Stevens as Receiver, appointed by the U.S. District Court for the District of Wyoming in Case No. 2:26-cv-00020-ABJ and exercising the powers of the board, indicating the company is under a court-appointed receivership. No replacement director or compensatory arrangement was disclosed in this filing.

• · Company is operating under a court-appointed Receiver, who is exercising the powers of the board of directors, appointed by the U.S. District Court for the District of Wyoming (Case No. 2:26-cv-00020-ABJ).
• · Resignation was delivered in writing to the Receiver on October 2, 2026, and the filing discloses no successor director or board appointment.
• · Company is an emerging growth company; registered under Section 12(g) (Commission File No. 000-56747) with no securities registered under Section 12(b).